{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:54:57Z","timestamp":1791381297225,"version":"4.3.3"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.pcad.2023.07.006","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T13:30:21Z","timestamp":1690464621000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Lipoprotein(a) in clinical practice: A guide for the clinician"],"prefix":"10.1016","volume":"79","author":[{"given":"Chayakrit","family":"Krittanawong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil Sagar","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham H.","family":"El-Sherbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pcad.2023.07.006_bb0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(a) and calcific aortic valve stenosis: a systematic review","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2023.07.006_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2023.06.002","article-title":"The common pathobiology between coronary artery disease and calcific aortic stenosis: Evidence and clinical implications","author":"Abdul-Rahman","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2023.07.006_bb0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.amjcard.2020.03.043","article-title":"Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations","volume":"126","author":"Shah","year":"2020","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2023.07.006_bb0020","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Lipoprotein(a)","year":"2009","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.pcad.2023.07.006_bb0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/HCO.0000000000000300","article-title":"Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis","volume":"31","author":"Yeang","year":"2016","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2023.07.006_bb0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jama.2021.3632","article-title":"Lipoprotein(a) and cardiovascular diseases","volume":"326","author":"Miksenas","year":"2021","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.pcad.2023.07.006_bb0035","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the multi-ethnic study of atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pcad.2023.07.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6144","key":"10.1016\/j.pcad.2023.07.006_bb0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.pcad.2023.07.006_bb0050","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.pcad.2023.07.006_bb0055","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.pcad.2023.07.006_bb0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a)","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2023.07.006_bb0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit Arterial Wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation."},{"issue":"6222","key":"10.1016\/j.pcad.2023.07.006_bb0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/339303a0","article-title":"Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis","volume":"339","author":"Hajjar","year":"1989","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.pcad.2023.07.006_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2023.07.006_bb0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(99)00064-7","article-title":"Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux","volume":"143","author":"Nielsen","year":"1999","journal-title":"Atherosclerosis."},{"issue":"1","key":"10.1016\/j.pcad.2023.07.006_bb0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"issue":"39","key":"10.1016\/j.pcad.2023.07.006_bb0090","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.07.006_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"issue":"24","key":"10.1016\/j.pcad.2023.07.006_bb0100","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"10.1016\/j.pcad.2023.07.006_bb0105","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2023.07.006_bb0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12881-020-01003-3","article-title":"Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification","volume":"21","author":"Pechlivanis","year":"2020","journal-title":"BMC Med Genet"},{"issue":"6","key":"10.1016\/j.pcad.2023.07.006_bb0115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pcad.2023.07.006_bb0120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case\u2013control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"6","key":"10.1016\/j.pcad.2023.07.006_bb0125","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacasi.2022.08.015","article-title":"Lipoprotein(a) and cardiovascular disease in Chinese population","volume":"2","author":"Li","year":"2022","journal-title":"JACC Asia"},{"issue":"5","key":"10.1016\/j.pcad.2023.07.006_bb0130","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/ATVBAHA.120.315300","article-title":"Genome-wide association study and identification of a protective missense variant on lipoprotein(a) concentration: protective missense variant on lipoprotein(a) concentration\u2014brief report","volume":"41","author":"Said","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.pcad.2023.07.006_bb0135","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.pcad.2023.07.006_bb0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ijs.12136","article-title":"Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke","volume":"9","author":"Sultan","year":"2014","journal-title":"Int J Stroke"},{"issue":"19","key":"10.1016\/j.pcad.2023.07.006_bb0145","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease","volume":"55","author":"Erqou","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2023.07.006_bb0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2023.07.006_bb0155","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.pcad.2023.07.006_bb0160","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.jacc.2012.02.093","article-title":"Calcific Aortic Stenosis","volume":"60","author":"Dweck","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.pcad.2023.07.006_bb0165","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2023.07.006_bb0170","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation."},{"issue":"23","key":"10.1016\/j.pcad.2023.07.006_bb0175","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pcad.2023.07.006_bb0180","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.pcad.2023.07.006_bb0185","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, Rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation."},{"issue":"3","key":"10.1016\/j.pcad.2023.07.006_bb0190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-2275(20)41683-9","article-title":"Radioimmunoassay of human plasma Lp(a) lipoprotein","volume":"18","author":"Albers","year":"1977","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.pcad.2023.07.006_bb0195","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacl.2022.02.004","article-title":"Quantifying the contribution of lipoprotein(a) to all apoB containing particles","volume":"16","author":"Chilazi","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2023.07.006_bb0200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pcad.2022.01.002","article-title":"Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know","volume":"73","author":"Virani","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.pcad.2023.07.006_bb0205","article-title":"First WHO\/IFCC international reference reagent for lipoprotein(a) for immunoassay \u2013 Lp(a) SRM 2B","volume":"42","author":"Dati","year":"2004","journal-title":"Clin Chem Lab Med CCLM"},{"issue":"4","key":"10.1016\/j.pcad.2023.07.006_bb0210","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.pcad.2023.07.006_bb0215","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.pcad.2023.07.006_bb0220","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.pcad.2023.07.006_bb0225","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.pcad.2023.07.006_bb0230","doi-asserted-by":"crossref","DOI":"10.1007\/BF00201550","article-title":"Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups","volume":"86","author":"Sandholzer","year":"1991","journal-title":"Hum Genet"},{"issue":"12","key":"10.1016\/j.pcad.2023.07.006_bb0235","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","article-title":"Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans","volume":"37","author":"Marcovina","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2023.07.006_bb0240","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","author":"Patel","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2023.07.006_bb0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjcard.2021.12.014","article-title":"Impact of lipoprotein(a) as a residual risk factor in long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statins","volume":"168","author":"Takahashi","year":"2022","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2023.07.006_bb0250","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation."},{"issue":"3","key":"10.1016\/j.pcad.2023.07.006_bb0255","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pcad.2023.07.006_bb0260","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women","volume":"72","author":"Cook","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2023.07.006_bb0265","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a)","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.pcad.2023.07.006_bb0270","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.pcad.2023.07.006_bb0275","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA."},{"issue":"11","key":"10.1016\/j.pcad.2023.07.006_bb0280","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation."},{"issue":"25","key":"10.1016\/j.pcad.2023.07.006_bb0285","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation."},{"issue":"29","key":"10.1016\/j.pcad.2023.07.006_bb0290","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"issue":"39","key":"10.1016\/j.pcad.2023.07.006_bb0295","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.pcad.2023.07.006_bb0300","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a)","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.pcad.2023.07.006_bb0305","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.07.006_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100478","article-title":"Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes","volume":"14","author":"Kelsey","year":"2023","journal-title":"Am J Prev Cardiol"},{"issue":"14","key":"10.1016\/j.pcad.2023.07.006_bb0315","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2023.07.006_bb0320","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of Proprotein convertase Subtilisin\/Kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and Meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.pcad.2023.07.006_bb0325","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11883-014-0467-4","article-title":"The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations","volume":"17","author":"Agarwala","year":"2015","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"10.1016\/j.pcad.2023.07.006_bb0330","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s10557-020-07082-x","article-title":"Lipid-lowering biotechnological drugs: from monoclonal antibodies to antisense therapies\u2014a clinical perspective","volume":"35","author":"Jia","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"10.1016\/j.pcad.2023.07.006_bb0335","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism."},{"issue":"3","key":"10.1016\/j.pcad.2023.07.006_bb0340","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1311039","article-title":"Safety profile of extended-release niacin in the AIM-HIGH trial","volume":"371","author":"Anderson","year":"2014","journal-title":"N Engl J Med"},{"issue":"10155","key":"10.1016\/j.pcad.2023.07.006_bb0345","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.pcad.2023.07.006_bb0350","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.pcad.2023.07.006_bb0355","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2023.07.006_bb0360","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1194\/jlr.P027235","article-title":"Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia","volume":"53","author":"Arai","year":"2012","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.pcad.2023.07.006_bb0365","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?: lipid apheresis in LP(a) patients","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"issue":"9","key":"10.1016\/j.pcad.2023.07.006_bb0370","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10057","key":"10.1016\/j.pcad.2023.07.006_bb0375","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcad.2023.07.006_bb0380","first-page":"197","article-title":"Lipoprotein apheresis","volume":"33","author":"Moriarty","year":"2015","journal-title":"Cardiol Clin"},{"issue":"14","key":"10.1016\/j.pcad.2023.07.006_bb0385","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.283.14.1845","article-title":"Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause","volume":"283","author":"Shlipak","year":"2000","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.pcad.2023.07.006_bb0390","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"13","key":"10.1016\/j.pcad.2023.07.006_bb0395","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody Evolocumab (AMG 145)","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2023.07.006_bb0400","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of Lipoprotein(a) with atherosclerotic plaque progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.pcad.2023.07.006_bb0405","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.pcad.2023.07.006_bb0410","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.pcad.2023.07.006_bb0415","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.pcad.2023.07.006_bb0420","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation."}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:22:48Z","timestamp":1758500568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062023000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":84,"alternative-id":["S0033062023000725"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2023.07.006","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) in clinical practice: A guide for the clinician","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2023.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}